

## TARGET IDENTIFICATION AND VALIDATION IN DRUG DISCOVERY

Friday 24 October 2025

AstraZeneca - The Discovery Centre (DISC), 1 Francis Crick Ave, Cambridge Biomedical Campus, CB2 0AA, UK

This meeting is supported by:



### PROGRAMME

08.30 - 09.25      Arrival, registration and coffee

09.25 - 09.30      Welcome and introduction  
*Daniel O Donovan, AstraZeneca and SMR Chair*

#### Session 1

09.30 - 10.10      1-1 Navigating Challenges and Opportunities in Oncology Target Discovery  
*Larissa Carnevalli, AstraZeneca*

10.10 - 10.50      1-2 Open Targets, Target Identification & Prioritisation in Partnership  
*David Hulcoop, EMBL- EBI*

10.50 - 11.10      Coffee Break

#### Session 2

11.10 - 11.50      2-1 Can complex human in vitro models deliver better targets?  
*Erica Bello and Chun Hao Wong, Milner Institute*

11.50 - 12.30      2-2 Functional Genomics approaches for target identification  
*Gerry Crossan, AstraZeneca Functional Genomics Centre (FGC)*

12.30 - 13.30 Lunch and Networking

Session 3

13.30 - 14.10 3-1 Data-driven design of chiral covalent fragments for expansion of the ligandable cysteinome  
*William McCarthy, Francis Crick Institute*

14.10 - 14.50 3-2 Unlocking the Potential of Primary Cells in Target Discovery  
*Andrzej Mazan, Ryvu*

14.50 - 15.10 Coffee Break

Session 4

15.10 - 15.50 4-1 OGAP® Verify: A Proteomics Platform *with Enhanced Sensitivity, Specificity and Reliability* for Oncology Target Discovery  
*Martin Barnes, Oxford Biotherapeutics*

15.50 - 16.30 4-2 Reprogramming biology for Targeted Molecular Glue Discovery  
*Darcie Mulhearn, PhoreMost*

16.30 Closing remarks  
*Dr Daniel O Donovan, AstraZeneca and SMR Chair*

**There will be a drinks reception following the meeting**